Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Activity of Rituximab(HLX01) in Combination With Pegylated Interferon α-2b in Patients With Newly Diagnosed Advanced Indolent B-cell Lymphoma: a Single-arm, Multicenter, Phase 2 Study

Next Previous
Trial Profile

Safety and Activity of Rituximab(HLX01) in Combination With Pegylated Interferon α-2b in Patients With Newly Diagnosed Advanced Indolent B-cell Lymphoma: a Single-arm, Multicenter, Phase 2 Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Rituximab (Primary) ; Entecavir
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphatic disorders; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms RIPPLE

Most Recent Events

  • 12 Dec 2023 Results of long-term follow-up data,presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 06 Apr 2022 Planned primary completion date changed from 16 Jan 2022 to 16 Jun 2022.
  • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top